These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36299883)

  • 1. Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib.
    Chen L; Li C; Bai H; Li L; Chen W
    Front Pharmacol; 2022; 13():960186. PubMed ID: 36299883
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib.
    Chen L; Li L; Chen W
    Clin Pharmacol Drug Dev; 2022 Jun; 11(6):724-733. PubMed ID: 34995400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen.
    Chen L; Zhu L; Li M; Li N; Qi F; Wang N
    AAPS PharmSciTech; 2019 Jan; 20(1):24. PubMed ID: 30604153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Influence of Different Triazole Antifungal Agents on the Pharmacokinetics of Cyclophosphamide.
    Cai T; Liao Y; Chen Z; Zhu Y; Qiu X
    Ann Pharmacother; 2020 Jul; 54(7):676-683. PubMed ID: 31893943
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
    Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
    CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
    Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
    Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
    Tariq B; Ou YC; Stern JC; Mundra V; Wong Doo N; Walker P; Lewis KL; Lin C; Novotny W; Sahasranaman S; Opat S
    Leuk Lymphoma; 2023 Feb; 64(2):329-338. PubMed ID: 36480811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors.
    Pilla Reddy V; Fretland AJ; Zhou D; Sharma S; Chen B; Vishwanathan K; McGinnity DF; Xu Y; Ware JA
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):451-464. PubMed ID: 34080039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
    Xu L; Yu S; Liu H; Yi B; Wang G; Liu Y
    Eur J Clin Pharmacol; 2022 Sep; 78(9):1435-1446. PubMed ID: 35680661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS; Ou YC; Trotman J; Opat S
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
    Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
    Zhou D; Podoll T; Xu Y; Moorthy G; Vishwanathan K; Ware J; Slatter JG; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2019 Jul; 8(7):489-499. PubMed ID: 31044521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
    Qi F; Zhu L; Li N; Ge T; Xu G; Liao S
    Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triazole antifungal agents in invasive fungal infections: a comparative review.
    Lass-Flörl C
    Drugs; 2011 Dec; 71(18):2405-19. PubMed ID: 22141384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
    Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.
    Robak T; Witkowska M; Smolewski P
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
    Chen J; Kinoshita T; Gururaja T; Sukbuntherng J; James D; Lu D; Whang J; Versele M; Chang BY
    Eur J Haematol; 2018 Jul; ():. PubMed ID: 30030853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.